Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com

Research analysts at StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note issued on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Trading Up 5.8 %

EVOK stock opened at $5.08 on Wednesday. The company has a market capitalization of $43.67 million, a P/E ratio of -2.78 and a beta of 0.38. The business has a 50 day simple moving average of $4.96 and a 200-day simple moving average of $5.84. Evoke Pharma has a twelve month low of $3.54 and a twelve month high of $18.60.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Evoke Pharma had a negative return on equity of 964.25% and a negative net margin of 86.74%. The business had revenue of $2.55 million for the quarter.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.